DEFA14A: Alzamend Neuro Corrects Voting Share Count in Proxy Statement Supplement

Alzamend Neuro issues a supplement to its proxy statement, correcting the number of votes entitled to be cast at the upcoming special meeting of stockholders.

Summary

• Alzamend Neuro, Inc. has issued a supplement to its definitive proxy statement filed on May 31, 2024.
• The supplement corrects the number of shares of Capital Stock entitled to vote at the Special Meeting of Stockholders scheduled for July 8, 2024.
• The company initially calculated 1,719,537 votes for Series A Preferred Stock, but the correct number is 1,375,310 due to NYSE American rules.
• This correction affects the quorum calculation for the meeting.
• The term 'Eligible Capital Stock' is defined as 9,782,611 shares for Proposal No. 1 and 11,157,921 shares for Proposal No. 2.
• All other information in the original proxy statement remains unchanged.

Sentiment

Score: 7

Explanation: The document is a routine correction of a proxy statement, indicating a neutral to slightly positive sentiment due to the company's proactive approach to accuracy.

Positives

• The company is proactively correcting an error in its proxy statement to ensure accurate voting procedures.

Negatives

• The initial miscalculation of voting shares could have led to confusion or inaccuracies in the voting process.

Risks

• Failure to properly address the voting share discrepancy could lead to challenges to the validity of the meeting's outcome.

Future Outlook

The supplement clarifies voting procedures for the upcoming Special Meeting of Stockholders.

Industry Context

Proxy statement supplements are common when companies need to correct or update information previously disclosed to shareholders.

Stakeholder Impact

• Shareholders will have accurate information for voting decisions.
• The correction ensures compliance with regulatory requirements.

Next Steps

• Stockholders should review the supplement before voting at the Special Meeting.
• The company will hold the Special Meeting on July 8, 2024.

Key Dates

Keywords

proxy statement, Alzamend Neuro, special meeting, voting shares, Series A Preferred Stock, quorum, NYSE American, capital stock